Wolverine Trading, LLC Corvus Pharmaceuticals, Inc. Call Options Transaction History

Wolverine Trading, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.78 - $5.92 $48,950 - $162,800	27,500 New	27,500 $145,000
Q2 2023 Aug 23, 2023	BUY	$1.0 - $3.86 $6,900 - $26,634	6,900 Added 55.2%	19,400 $44,000
Q1 2023 May 15, 2023	BUY	$0.65 - $0.92 $8,125 - $11,500	12,500 New	12,500 $10,000
Q2 2022 Aug 15, 2022	SELL	$0.87 - $2.03 $11,919 - $27,810	-13,700 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.46 - $2.48 $20,002 - $33,976	13,700 New	13,700 $22,000
Q4 2021 Feb 14, 2022	SELL	$2.34 - $5.31 $74,178 - $168,327	-31,700 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.89 - $8.53 $59,913 - $270,401	31,700 New	31,700 $200,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $242M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.